6533b821fe1ef96bd127c044

RESEARCH PRODUCT

Pleuropulmonary Changes Induced by Drugs in Patients with Hematologic Diseases

Philippe Camus

subject

Oncologymedicine.medical_specialtybusiness.industryBortezomibTotal body irradiationFludarabineDasatinibTransplantationThalidomidehemic and lymphatic diseasesInternal medicinemedicineRituximabbusinessLenalidomidemedicine.drug

description

Patients with hematologic diseases who are being treated with therapy drugs, or receive radiation therapy or blood transfusions may develop a host of potentially fatal infectious and noninfectious pulmonary complications [1]. The increased complexity of multimodality and high-dose treatment regimens with the intended benefit of augmented antineoplastic efficacy and prolonged disease-free survival, the use of a panel of novel drugs to treat malignant and nonmalignant hematologic conditions (e.g., azacytidine, bortezomib, cladribine, dasatinib, fludarabine, imatinib, lenalidomide, rituximab, and thalidomide), total body irradiation (TBI) and hematopietic stem cell transplantation (HSCT) have increased the incidence of severe sometimes life-threatening pulmonary complications.

yearjournalcountryeditionlanguage
2010-12-22
https://doi.org/10.1007/978-3-642-15742-4_31